Presenter Speech
Terence Flynn (Analysts)
Okay. Great. Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Very pleased to be hosting Royalty Pharma
W
USA
EnglishUK
EnglishIndia
EnglishAustralia
EnglishCanada
EnglishFrance
FrançaisSuisse
FrançaisEspaña
EspañolDeutschland
DeutschÖsterreich
DeutschSchweiz
DeutschBelgië
NederlandsNederland
NederlandsItalia
ItalianoSverige
Svenska
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.60 USD | -0.78% |
|
+0.96% | +27.99% |
Feb. 12 | Biogen Expects Decline in 2025 Revenue, Reports Fourth-Quarter Beat | MT |
Feb. 12 | Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D | MT |
Presenter Speech
Terence Flynn (Analysts)
Okay. Great. Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Very pleased to be hosting Royalty Pharma
W